Materials and methods for treatment of usher syndrome type 2A

Patent metadata

Field	Value
Publication number	US-12215316-B2
Application number	US-202117360578-A
Country	US
Kind code	B2
Filing date	Jun 28, 2021
Priority date	Dec 21, 2017
Publication date	Feb 4, 2025
Grant date	Feb 4, 2025

Abstract

The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A.

First claim

What is claimed is:

1. An in vivo method for treating a patient with Usher Syndrome Type 2A, the method comprising: editing an USH2A gene containing an IVS40 mutation in eye cells of the patient, wherein the editing comprises introducing into the eye cell one or more DNA endonucleases selected from the group consisting of Cas9 and Cpf1 endonucleases and nickases and one or more guide ribonucleic acids (gRNAs) comprising a spacer sequence complementary to a sequence with or near intron 40 of the USH2A gene to effect one or more SSBs or DSBs within or near intron 40 or the USH2A gene the results in a correction and results in restoration of usherin protein function.

2. A gRNA or sgRNA comprising a nucleotide sequence set forth in SEQ ID NO: 5321, SEQ ID NO: 5323, SEQ ID NO: 5325, SEQ ID NO: 5327, or SEQ ID NO: 5328.

3. A gRNA or sgRNA comprising;
a) SEQ ID NO: 5321 and any one of SEQ ID NOs: 5267-5269;
b) SEQ ID NO: 5323 and any one of SEQ ID NOs: 5267-5269;
c) SEQ ID NO: 5325 and any one of SEQ ID NOs: 5267-5269;
d) SEQ ID NO: 5327 and any one of SEQ ID NOs: 5267-5269; or
e) SEQ ID NO: 5328 and any one of SEQ ID NOs: 5267-5269.

4. A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of a Cas9 endonuclease and nickases and a Cfp1 endonuclease and a gRNA or sgRNA to eye cells of the patient, wherein the gRNA or sgRNA comprises SEQ ID NO: 5321, SEQ ID NO: 5323, SEQ ID NO: 5325, SEQ ID NO: 5327, or SEQ ID NO: 5328.

5. A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of a Cas9 endonuclease and nickases and a Cfp1 endonuclease and a gRNA or sgRNA to eye cells of the patient, wherein the gRNA or sgRNA comprises
a) SEQ ID NO: 5321 and any one of SEQ ID NOs: 5267-5269;
b) SEQ ID NO: 5323 and any one of SEQ ID NOs: 5267-5269;
c) SEQ ID NO: 5325 and any one of SEQ ID NOs: 5267-5269;
d) SEQ ID NO: 5327 and any one of SEQ ID NOs: 5267-5269; or
e) SEQ ID NO: 5328 and any one of SEQ ID NOs: 5267-5269.

6. A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of Cas9 and Cfp1 endonucleases and nickases and a first gRNA or sgRNA and second gRNA or sgRNA to eye cells of the patient, wherein
a) the first gRNA or sgRNA comprises SEQ ID NO: 5295 and the second gRNA or sgRNA comprises SEQ ID NO: 5279;
b) the first gRNA or sgRNA comprises SEQ ID NO: 5294 and the second gRNA or sgRNA comprises SEQ ID NO: 5300;
c) the first gRNA or sgRNA comprises SEQ ID NO: 5295 and the second gRNA or sgRNA comprises SEQ ID NO: 5300;
d) the first gRNA or sgRNA comprises SEQ ID NO: 5290 and the second gRNA or sgRNA comprises SEQ ID NO: 5300; or
e) the first gRNA or sgRNA comprises SEQ ID NO: 5277 and the second gRNA or sgRNA comprises SEQ ID NO: 5300.

7. A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of Cas9 and Cfp1 endonucleases and nickases and a first gRNA or sgRNA and second gRNA or sgRNA to eye cells of the patient, wherein
a) a first gRNA or sgRNA comprises SEQ ID NO: 5452 and the second gRNA or sgRNA comprises SEQ ID NO: 5449;
b) a first gRNA or sgRNA comprises SEQ ID NO: 5453 and the second gRNA or sgRNA comprises SEQ ID NO: 5449;
c) a first gRNA or sgRNA comprises SEQ ID NO: 5455 and the second gRNA or sgRNA comprises SEQ ID NO: 5457;
d) a first gRNA or sgRNA comprises SEQ ID NO: 5452 and the second gRNA or sgRNA comprises SEQ ID NO: 5451; or
e) a first gRNA or sgRNA comprises SEQ ID NO: 5448 and the second gRNA or sgRNA comprises SEQ ID NO: 5449.

Assignees

• Crispr Therapeutics Ag
• Bayer Healthcare Llc

Inventors

• Kantardzhieva Albena
• Noma Akiko
• Scaria Abraham

Classifications

• C12N2800/80

  Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N15/11 Primary

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title